Roflumilast
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Roflumilast |
| DrugBank ID | DB01656 |
| Brand Names (EU) | Daxas |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 97.24% |
Approved Indication (EMA)
Daxas is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | pulmonary hypertension | 97.24% | DL |
| 2 | kyphoscoliotic heart disease | 96.74% | DL |
| 3 | headache disorder | 93.14% | DL |
| 4 | female breast carcinoma | 92.79% | DL |
| 5 | trigeminal autonomic cephalalgia | 92.15% | DL |
| 6 | obsolete patella aplasia, coxa vara, and tarsal synostosis | 89.92% | DL |
| 7 | hypertrichosis (disease) | 89.03% | DL |
| 8 | Ambras type hypertrichosis universalis congenita | 89.02% | DL |
| 9 | malformation syndrome with odontal and/or periodontal component | 88.26% | DL |
| 10 | pulmonary hypertension, primary, autosomal recessive | 88.05% | DL |
| 11 | syndrome with a Dandy-Walker malformation as major feature | 88.02% | DL |
| 12 | familial clubfoot due to 17q23.1q23.2 microduplication | 87.34% | DL |
| 13 | coxopodopatellar syndrome | 87.22% | DL |
| 14 | chromosome 17q23.1-q23.2 deletion syndrome | 86.97% | DL |
| 15 | isolated genetic hair shaft abnormality | 86.90% | DL |
| 16 | cor pulmonale | 86.86% | DL |
| 17 | mycotic corneal ulcer | 86.04% | DL |
| 18 | scalp dermatosis | 85.25% | DL |
| 19 | primary hereditary glaucoma | 85.23% | DL |
| 20 | open-angle glaucoma | 84.19% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.